JCR Pharma announced that it completed the share buyback on July 22, 2026. The shares purchased were common shares, and the total amount spent was 98,496,000 yen. The purpose of the buyback was to improve capital efficiency and return value to shareholders.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4552","jir_company_name":"JCR Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-07-22","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4552-20260722-01.pdf","jir_short_summary":"JCR Pharma announced that it completed the share buyback on July 22, 2026. The shares purchased were common shares, and the total amount spent was 98,496,000 yen. The purpose of the buyback was to improve capital efficiency and return value to shareholders.","jir_summary":"### Overview of the Buyback\nJCR Pharma completed its share buyback on July 22, 2026. The shares purchased were common shares of the Company, with a total amount of 98,496,000 yen. This buyback was conducted to enhance capital efficiency and improve shareholder returns. Specific details regarding the method and number of shares bought back are not disclosed, but the remaining balance of treasury shares has decreased as a result of the buyback.\n\n### Impact on Shareholders and Future Outlook\nThe share buyback will mitigate dilution of outstanding shares and is expected to enhance shareholder value. As a result of the buyback, the ratio of treasury stock will decrease, and capital efficiency is anticipated to improve. The Company will continue shareholder return policies as part of its capital strategy aiming to maximize shareholder value.","jir_financial_highlights":"Amount of Buyback: 98,496,000 yen (Unknown)\nType of Shares Purchased: Common shares of the Company (Unknown)\nBuyback Date: 2026-07-22 (Unknown)","jir_category":"","jir_hashtags":"#JCRPharma, #ShareBuyback, #CapitalStrategy","jir_key_figures":"Amount of Buyback: 98,496,000 yen\nType of Shares Purchased: Common shares of the Company\nBuyback Date: 2026-07-22","jir_meta_title":"\u3010JCR Pharma\u3011Completion of Share Buyback\uff5cEnhancing Capital Efficiency in July 2026","jir_meta_description":"JCR Pharma completed its share buyback on July 22, 2026. The buyback amount was 98,496,000 yen, aimed at improving capital efficiency and returning value to shareholders, detailed in the announcement.","jir_og_title":"\u3010JCR Pharma\u3011Share Buyback Completed\uff5cEnhancing Capital Efficiency July 2026","jir_og_description":"JCR Pharma has completed its share buyback. The amount was 98,496,000 yen, part of its capital strategy to enhance shareholder value.","jir_og_image_url":"\/assets\/og\/company-share_buyback.jpg","jir_chart_data_collection":"[]","ir_related_company":9680,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-86634","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n